Fig. 4.

Increased M2 macrophages in Ccl5^−/− mice at the late phase of APAP treatment. a–d APAP treatment in both Ccl5^−/− and WT mice at 36 h. a Representative MoMF (CD11b^highF4/80^int) and KC (CD11b^int F4/80^high) profiles of CD45⁺ liver nongranulocytes from Ccl5^−/− and WT mice 36 h after APAP treatment and the quantification of the proportion of MoMFs and KCs relative to total CD45⁺ liver nongranulocytes (n = 4–6). b Representative FACS plots and the statistical quantification of CD206⁺ hepatic macrophages (hMφ) (n = 4–6). c The relative expression of M1 markers (iNOS, IL-1β, and TNFα) and M2 markers (Arg1, Ym1, and CD206) was determined in FACS-sorted hepatic macrophages (CD45⁺CD11b⁺F4/80⁺) (n = 4). d Representative images and the statistical quantification of hepatic cells positive for CD68 (a panmacrophage marker) and Ym1 (an M2 macrophage marker) in liver sections (original magnification = ×400, scale bar = 50 μm). The data are shown as the means ± SEM, *P < 0.05, **P < 0.01. hMφ hepatic macrophages